MedTrace Logo

Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial

NCT04390022 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-12-17

Study results available
· View outcomes & findings →

Summary

SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.

Conditions

Interventions

DRUG

Ivermectin

Single dose of STROMECTOL® tablets at 400mcg/kg

DRUG

Placebo

Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.

Sponsors & Collaborators

  • Barcelona Institute for Global Health

    collaborator OTHER

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Carlos J Chaccour, MD PhD · Clinica Universidad de Navarra and Barcelona Institute of Global Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2020-09-17
Completion
2020-10-09

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390022 on ClinicalTrials.gov